Genmab (Otc) ( (GMAB) ) has released its Q1 earnings. Here is a breakdown of the information Genmab (Otc) presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genmab, a biotechnology company based in Denmark, specializes in the development of antibody therapeutics for cancer treatment, leveraging its proprietary technology platforms. In its latest earnings report, Genmab announced significant progress in its product pipeline, including the approval of EPKINLY for follicular lymphoma in Japan and Tivdak for cervical cancer in both Japan and the European Union. The company’s revenue for the first quarter of 2025 increased by 19% to $715 million, driven by higher royalties from DARZALEX and Kesimpta, as well as EPKINLY sales. Operating profit rose to $188 million, reflecting the company’s strategic focus on expanding its product reach and pipeline development. Looking ahead, Genmab maintains its financial guidance for 2025, anticipating continued growth through its collaborations and product innovations.